10128 Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments or request more 

information on the proposed project 

contact: Jackie Lavigne, Office of 

Education, Division of Cancer 

Epidemiology and Genetics, 9609 

Medical Center Drive, MSC 9776, 

Bethesda, MD 20892–9776 or call nontoll-free number 240–376–7237 or Email 

your request, including your address to: 

lavignej@mail.nih.gov. Formal requests 

for additional plans and instruments 

must be requested in writing. 

Proposed Collection: Division of 

Cancer Epidemiology and Genetics 

(DCEG) Fellowship Program and 

Summer Student Applications (NCI), 

Existing Collection in Use without OMB 

Control Number, National Cancer 

Institute (NCI), National Institutes of 

Health (NIH). 

Need and Use of Information 

Collection: The Division of Cancer 

Epidemiology and Genetics (DCEG) 

Office of Education (OE) administers a 

variety of programs and initiatives to 

recruit pre-college through post-doctoral 

educational level individuals into the 

Intramural Research Program to 

facilitate their development into future 

biomedical scientists. DCEG trains postdoctoral, doctoral candidates, graduate 

and baccalaureate students, through full 

time fellowships, summer fellowships, 

and internships in preparation for 

research careers in cancer epidemiology 

and genetics. The proposed information 

collection involves brief online 

applications completed by applicants to 

the full time and the summer fellowship 

programs. Full-time fellowships 

include: Full-time Equivalents (FTE) 

and non-FTE fellowships for US 

citizens, permanent residents and 

international fellows. These 

applications are essential to the 

administration of these training 

programs as they enable OE to 

determine the eligibility and quality of 

potential awardees; to assess their 

potential as future scientists; to 

determine where mutual research 

interests exist; and to make decisions 

regarding which applicants will be 

proposed and approved for traineeship 

awards. In each case, completing the 

application is voluntary, but in order to 

receive due consideration, the 

prospective trainee is encouraged to 

complete all relevant fields. The 

information is for internal use to make 

decisions about prospective fellows and 

students that could benefit from the 

DCEG program. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

175. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hours 

Fellowship Program Application ................... Full-time Fellows ................... 150 1 30/60 75 

Summer Program Application ....................... Summer Students ................. 300 1 20/60 100 

Dated: February 19, 2015. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–03789 Filed 2–24–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request; Assessment of 

Oncology Nursing Education and 

Training in Low and Middle Income 

Countries (NCI) 

SUMMARY: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH), has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on July 8, 2014, 

Vol. 79, page 38542 and allowed 60- 

days for public comment. One public 

comment was received on July 9, 2014. 

The purpose of this notice is to allow an 

additional 30 days for public comment. 

The National Cancer Institute (NCI), 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: NIH Desk Officer. 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments or request more 

information on the proposed project, 

contact: Annette Galassi, Center for 

Global Health, National Cancer Institute, 

9609 Medical Center Dr., Rm. 3W250, 

Rockville, MD 20850 or call non-tollfree number 240–276–6632 or Email 

your request, including your address to: 

agalassi@mail.nih.gov. Formal requests 

for additional plans and instruments 

must be requested in writing. 

Proposed Collection: Assessment of 

Oncology Nursing Education and 

Training in Low and Middle Income 

Countries, 0925–NEW, National Cancer 

Institute (NCI), National Institutes of 

Health (NIH). 

Need and Use of Information 

Collection: This submission is a request 

for OMB to approve the Assessment of 

Oncology Nursing Education and 

Training in Low and Middle Income 

Countries (LMICs). NCI-Designated 

Cancer Centers have a range of 

international activities, some of which 

are funded by NCI, but many of which 

are not. These international activities 

may include oncology nursing 

education and training in LMICs, but 

the extent of these activities across 

cancer centers is unknown. The 

proposed assessment requests 

information about oncology nursing 

education and training projects 

including: descriptions of projects, 

partner organizations, types of activities, 

cost, and impact. The information will 

be collected annually. NCI’s Center for 

Global Health (CGH) is in the process of 

developing its strategic plan for 

oncology nursing education in LMICs. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices 10129 

This information will help inform this 

strategic planning process and provide 

evidence to inform decisions on 

potential investments in grants for 

oncology nursing education in LMICs. 

Additionally, this information will be 

used in an online, interactive map that 

is being developed by CGH which will 

allow external organizations, such as 

cancer centers, to explore what projects 

are being done in which countries, 

which will facilitate collaborations and 

minimize duplication. The frequency of 

the data collection will be once per year 

although respondents may have more 

than one response if they have up to 

three projects. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

51. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents 

Number of 

respondents/ 

year 

Number of 

responses per 

respondent 

Average burden per response 

(in hours) 

Total annual 

burden hours 

Directors of Nursing ......................................................................................... 68 3 15/60 51 

Dated: February 19, 2015. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–03788 Filed 2–24–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

HbF Induction Therapy for Sickle Cell 

Disease and Thalassemias 

Description of Technology: Sickle cell 

disease and thalassemia are hereditary 

disorders marked by the disruption in 

the pathways responsible for carrying 

oxygen to red blood cells. Symptoms 

associated with these disorders include 

anemia, jaundice, and severe pain. It has 

been shown that mutations during the 

development of fetal to adult 

hemoglobin can contribute to a delay in 

red blood cell maturity underlying 

sickle cell disease. As a result, there has 

been an increased focus on treatments 

that promote the induction of fetal 

hemoglobin (HbF) to improve clinical 

symptoms and ameliorate the severity of 

the diseases. Researchers at the National 

Institute of Diabetes and Digestive and 

Kidney Diseases have identified 

methods of increasing fetal hemoglobin 

by increasing the expression of Lin28 or 

decreased expression of let-7 microRNAs. The lead inventor and colleagues 

have developed novel lentiviral 

expression vectors containing 

hemoglobin regulators under the control 

of erythroid-specific promoters that can 

be used to increase Hbf expression 

without affecting the maturity of red 

blood cells. In addition, they have 

found, through the use of tough decoy 

inhibition of Let-7 micro-RNAs, a 

selection of Let-7 genes with greater 

involvement in HbF expression. This 

technology could lead to development 

of novel HbF induction therapies that 

reactivate and reduce the aberrant 

pathologies associated with human 

sickle-cell anemia and beta thalassemia. 

Potential Commercial Applications: 

• Ex vivo and in vivo therapeutics for 

treatment of sickle-cell anemia and beta 

thalassemias. 

• Potential use in combination with 

other transduction methods for unique 

therapeutic strategies. 

Competitive Advantages: 

• Reduced production of symptomassociated adult hemoglobin. 

• Lin28 overexpression at defined 

stage of hematopoietic cell 

development. 

• Therapeutic increases in patient 

HbF expression at lower viral titers than 

current direct transduction methods. 

• Improved safety and reduced 

toxicity as a result of erythroid-specific 

expression. 

Development Stage: 

• Early-stage 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Jeffery L. Miller, Yuanwei 

T. Lee, Jaira F. de Vasconcellos, Colleen 

K. Byrnes (all of NIDDK) 

Intellectual Property: HHS Reference 

No. E–249–2014/0—US Provisional 

Application No. 62/046,247 filed 

September 5, 2014 

Related Technology: HHS Reference 

No. E–456–2013/2—PCT Application 

No. PCT/US2013/067811 filed October 

31, 2013, which published as WO 2014/ 

200557 on December 18, 2014 

Licensing Contact: Vince Contreras, 

Ph.D.; 301–435–4711; contrerasv@

mail.nih.gov 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize this 

technology. For collaboration 

opportunities, please contact Marguerite 

J. Miller at millermarg@niddk.nih.gov or 

301–496–9003. 

T Cell-Based Adoptive Transfer 

Immunotherapy for PolyomavirusAssociated Pathologies 

Description of Technology: Available 

for licensing are methods to generate T 

cells responsive to multiple 

polyomaviruses. The resulting T cell 

populations could be useful in treating 

immunosuppressed individuals with 

polyomavirus infections or 

polyomavirus-associated pathologies 

such as Merkel cell carcinoma (MCC), 

polyomavirus-associated nephropathy 

(PVAN), hemorrhagic cystitis, 


asabaliauskas on DSK5VPTVN1PROD with NOTICES